Ko Andrew H, Tempero Margaret A
Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th floor, San Francisco, CA 94115, USA.
Curr Oncol Rep. 2002 May;4(3):202-12. doi: 10.1007/s11912-002-0017-z.
Treatment of pancreatic cancer remains a challenging task that often requires a multidisciplinary approach to confer optimal response and, ideally, maximize survival. A combination of locoregional approaches such as surgery and radiotherapy, along with systemic therapies for eradication of micrometastases, should be considered both for patients who are operative candidates and for those with locally advanced, unresectable disease. How best to combine these modalities in terms of schedule, timing, and choice of agents is a question that continues to be actively investigated. Some of these data are equivocal or conflicting; thus standards of care for combined-modality treatment have not been uniformly accepted to date. This article provides an overview of combined-modality therapy, focusing on the major studies that have guided our current approach to the treatment of pancreatic cancer and examining new strategies that are likely to improve outcomes and survival for patients in the future.
胰腺癌的治疗仍然是一项具有挑战性的任务，通常需要多学科方法来实现最佳反应，并理想地延长生存期。对于可手术的患者以及局部晚期、不可切除疾病的患者，应考虑将手术和放疗等局部区域治疗方法与用于根除微转移的全身治疗相结合。如何在方案安排、时机选择和药物选择方面最佳地结合这些治疗方式，仍是一个正在积极研究的问题。其中一些数据模棱两可或相互矛盾；因此，联合治疗的护理标准至今尚未得到统一认可。本文概述了联合治疗，重点介绍了指导我们当前胰腺癌治疗方法的主要研究，并探讨了可能改善未来患者治疗效果和生存期的新策略。
